幽门螺旋杆菌感染在喉鳞癌发生发展中的作用及机制

doi:10.6040/j.issn.1673-3770.0.2018.202

摘要/Abstract

摘要： 目的探讨幽门螺旋杆菌(H.pylori)感染在喉鳞癌(LSCC)发生发展中的作用及可能机制。方法选取2016年3月至2018年2月期间就诊的患者124例,包括71例LSCC患者(LSCC组)和53例良性病变患者(对照组),采集喉黏膜组织标本和血清标本,采用PCR法和ELISA法检测两组组织和血清标本中H.pylori表达;分析H.pylori感染与LSCC患者病理特征间的关系;采用免疫组化法和PCR法检测H.pylori感染与未感染LSCC患者喉黏膜组织中RASSF1A和FHIT表达;采用PCR法和Western blotting法检测H.pylori感染FaDu细胞株RASSF1A和FHIT表达。结果 PCR检测结果显示,LSCC组与对照组H.pylori阳性表达率分别为71.83%(51/71)、26.42%(14/53),两组比较,P<0.001。PCR检测LSCC患者肿瘤组织和癌旁组织结果显示,6例(11.76%)患者只有肿瘤组织H.pylori呈阳性表达,24例(47.06%)患者只有癌旁组织H.pylori呈阳性表达,21例(41.18%)患者肿瘤组织和癌旁组织H.pylori均呈阳性表达,癌旁组织和肿瘤组织+癌旁组织H.pylori阳性表达率高于仅肿瘤组织H.pylori阳性表达率(P<0.05)。ELISA检测结果显示,LSCC组与对照组H.pyloriIgG抗体阳性率分别为78.87%(56/71)、64.15%(34/53),两组比较,P=0.069。单因素Logistic回归分析结果提示,H.pylori感染是喉癌的危险因素(OR=7.09, 95% CI 3.11~17.28, P<0.001)。纳入年龄、性别、吸烟史、饮酒史等因素,多因素Logistic回归分析结果提示,H.pylori感染是喉癌发生的独立危险因素(OR=6.94, 95% CI 2.87~15.31, P<0.001)。经Mann-whitney秩和检验分析,LSCC患者肿瘤不同发病部位、不同T分型及不同TNM分期H.pylori阳性表达率未见统计学差异(P>0.05)。免疫组化法检测结果显示,H.pylori感染与未感染LSCC患者喉黏膜组织中RASSF1A相对表达量分别为4.46±1.93、8.78±1.82,FHIT相对表达量分别为7.52±1.69、2.86±1.15,二者比较,P均<0.05。qRT-PCR法检测结果显示,H.pylori感染与未感染LSCC患者喉黏膜组织中RASSF1AmRNA相对表达量分别为0.74±0.10、0.19±0.06,FHITmRNA相对表达量分别为0.42±0.10、1.16±0.12,二者比较,P均<0.05。不同H.pylori干扰量与FaDu共培养48 h后,随着细菌干扰量升高,RASSF1A相对表达量升高(P均<0.05),而FHIT相对表达量降低(P均<0.05)。qRT-PCR法检测H.pylori干扰量分别为30∶1、100∶1、300∶1时RASSF1A表达量分别为0.20±0.08、0.43±0.10、1.41±0.08,FHIT表达量分别为1.26±0.22、0.70±0.13、0.18±0.10;Western blotting法检测H.pylori干扰量分别为30∶1、100∶1、300∶1时RASSF1A表达量分别为0.53±0.12、0.59±0.10、1.07±0.14,FHIT表达量分别为0.69±0.11、0.42±0.14、0.28±0.09。结论 H.pylori定植于喉癌患者的喉黏膜组织,是喉癌发生的重要危险因素;其机制可能通过影响抑癌基因RASSF1A和促癌基因FHIT的表达而参与调控喉癌的发生。

关键词: 喉鳞癌, 幽门螺旋杆菌, RASSF1A, FHIT

Abstract: Objective To examine the association between Helicobacter pylori and laryngeal squamous cell carcinoma(LSCC). Methods Between March 2016 and February 2018, 124 patients were randomly enrolled in this study, including 71 with LSCC and 53 with vocal cord polyps and epiglottic cysts. The expression of H.pylori in tissues was detected with polymerase chain reaction(PCR)technique, and serum H.pylori IgG was detected using enzyme-linked immunosorbent assay(ELISA). The expressions of RASSF1A and FHIT in tissues were detected using immunohistochemistry(IHC)and PCR. The expressions of RASSF1A and FHIT in FaDu cells under H.pylori co-culture conditions were detected using PCR and western blot tests. Results The H.pylori-positive rates in LSCC and control groups were 71.83%(51/71)and 26.42%(14/53)(P<0.001). Six patients(11.76%)only had H.pylori infection in tumor tissues, 24(47.06%)only had infection in adjacent cancer tissues, and 21(41.18%)had H.pylori infection in both tumor and adjacent cancer tissues (P<0.05). Positive rates for H.pylori IgG antibody were 78.87%(56/71)and 64.15%(34/53)in LSCC and control groups(P=0.069). H.pylori infection was a risk factor for LSCC by univariate logistic regression analysis(odds ratio ［OR］=7.09, 95% confidence interval ［CI］: 3.11-17.28, P<0.001). H.pylori infection was an independent risk factor for LSCC by multivariate logistic regression analysis(OR=6.94, 95% CI: 2.87-15.31, P<0.001). Mann-Whitney tests showed no statistically significant differences in H.pylori infection according to different lesion sites, T stages, and TNM stages(P>0.05). The expressions of RASSF1A in LSCC tissues with and without H.pylori infection were 4.46±1.93 and 8.78±1.82(P<0.05)using IHC. The expressions of FHIT in LSCC tissues with and without H.pylori infection were 7.52±1.69, 2.86±1.15(P<0.05)using IHC. The expressions of RASSF1A mRNA in LSCC tissues with and without H.pylori infection were 0.74±0.10 and 0.19±0.06(P<0.05)using quantitative real-time(qRT)-PCR. The expressions of FHIT in LSCC tissues with and without H.pylori infection were 0.42±0.10 and 1.16±0.12(P<0.05)using qRT-PCR. The expressions of RASSF1A mRNA in FaDu cells under H.pylori co-culture conditions(30∶1, 100∶1, 300∶1)were 0.20±0.08, 0.43±0.10, and 1.41±0.08, and FHIT mRNA expressions were 1.26±0.22, 0.70±0.13, and 0.18±0.10 by qRT-PCR. The expressions of RASSF1A mRNA in FaDu cells under H.pylori co-culture conditions(30∶1, 100∶1, 300∶1)were 0.53±0.12, 0.59±0.10, and 1.07±0.14, and FHIT mRNA expressions were 0.69±0.11, 0.42±0.14, and 0.28±0.09 by Western blotting. Conclusion There is significant evidence that H.pylori is present in the mucosa of laryngeal tissues in LSCC. H.pylori may be an important risk factor for the development of LSCC by regulating RASSF1A and FHIT expression.

Key words: Helicobacter pylori, Laryngeal squamous cell carcinoma, RASSF1A, FHIT

中图分类号:

R739.65

王奎荣,饶丽华,李专,段丙志. 幽门螺旋杆菌感染在喉鳞癌发生发展中的作用及机制[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 38-42.

WANG Kuirong, RAO Lihua, LI Zhuan, DUAN Bingzhi. Association between Helicobacter pylori and laryngeal squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 38-42.

参考文献

[1] 陈文杰,王斌全,高伟,等.喉癌流行病学特征及影响因素分析[J].中国当代医药,2015,22(12):43-46. CHEN Wenjie, WANG Binquan, GAO Wei, et al. Analysis of epidemiologic features and influence factors of carcinoma of larynx [J]. Chin Modern Med, 2015, 22(12):43-46.
[2] 朱奕,郭荦,王胜资.吸烟相关性喉癌遗传易感基因的初步研究[J].中国癌症杂志,2018,28(1):11-20. ZHU Yi, GUO Ying, WANG Shengzi. A preliminary study of genetic susceptibility to smoking-related laryngeal carcinoma[J]. Chin Oncol, 2018, 28(1):11-20.
[3] Sokic-Milutinovic A, Alempijevic T, Milosavljevic T. Role of Helicobacterpylori infection in gastric carcinogenesis: Current knowledge and future directions[J]. World J Gastroenterol, 2015, 21(41):11654-11672.
[4] 李颖怡,汪余勤. 幽门螺杆菌感染的治疗—当前的挑战[J].胃肠病学和肝病学杂志,2018,27(2):121-125. LI Yingyi, WANG Yuqin. Treatment of Helicobacter pylori infection—current challenges[J]. Chin J Gastroenterol Hepatol, 2018, 27(2):121-125.
[5] Kariya S, Okano M, Nishizaki K. An association between Helicobacter pylori and upper respiratory tract disease: Fact or fiction[J]. World J Gastroenterol, 2014, 20(6):1470-1484.
[6] Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis[J]. Lancet, 1983, 1(8336):1273.
[7] Testerman TL, Morris J. Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment[J]. World J Gastroenterol, 2014, 20(36):12781-12808.
[8] Amizadeh M, Shamsadini A, Arabzadeh A, et al. Association of cagA Positive Helicobacter pylori Infection and Laryngeal Squamous Cell Carcinoma: A PCR Approach[J]. Indian J Otolaryngol Head Neck Surg, 2015, 67(Suppl 1):51-55.
[9] Gong H, Shi Y, Xiao X, et al. Alterations of microbiota structure in the larynx relevant to laryngeal carcinoma[J]. Sci Rep, 2017, 7(1):5507.
[10] Grandis JR, Perez-perez GI, Yu VL, et al.Lack of serologic evidence for helicobacter pylori in head and neck cancer[J]. Head Neck, 1997, 19(3):216-218.
[11] Titiz A, Ozcakir O, Ceyhan S, et al. The presence of helicobacter pylori in the larynx pathologies[J]. Auris Nasus Larynx, 2008, 35(4):534-538.
[12] Lee TG, Jeong EH, Kim SY, et al. Fhit, a tumor suppressor protein, induces autophagy via 14-3-3τ in non-small cell lung cancer cells[J]. Oncotarget, 2017, 8(19):31923-31937.
[13] Jiménez AP, Traum A, Boettger T, et al. The tumor suppressor RASSF1 Ainduces the YAP1 target gene ANKRD1 that is epigenetically inactivated in human cancersand inhibits tumor growth[J]. Oncotarget, 2017, 8(51):88437-88452.
[14] 宋春丽,呼君瑜,李美艳,等.FHIT、C-myc在宫颈癌中的表达及其与高危型HPV感染的相关性[J].中国肿瘤,2016,25(5):395-399. SONG Chunli, HU Junyu, LI Meiyan, et al. Expression of FHIT and C-myc in cervical cancer and its correlation with high-risk HPV infection[J]. Bulletin Chinese Cancer, 2016, 25(5):395-399.
[15] 别远志,孙敬武,李万举.RASSF1A基因启动子甲基化状态与喉癌关系的实验研究[J].中国中西医结合耳鼻咽喉科杂志,2016,24(5):335-340. BIE Yuanzhi, SUN Jingwu, LI Wanju. Experimental study on the relationship between RASSF1A gene promoter methylation status and laryngeal carcinoma [J]. Chin J Otorhinolaryngol Int Med, 2016, 24(5):335-340.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed